3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Endometrial Neoplasms
10
Ovarian Neoplasms
7
Breast Neoplasms
4
Neoplasms
2
Fallopian Tube Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Low Grade Serous Ovarian Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Endometrioid Adenocarcinoma
1
ER+ HER2- Advanced Breast Cancer
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
2
Nivolumab
2
Carboplatin
2
tislelizumab
1
spartalizumab
1
ribociclib
1
obinutuzumab
1
naptumomab estafenatox
1
durvalumab
1
abemaciclib
1
Polymerase Chain Reaction
1
Mass Spectrometry
1
In Situ Hybridization, Fluorescence
1
Immunohistochemistry
1
Fulvestrant
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
abemaciclib
×
Gynecologic
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled